Commodore Capital LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1831942) · Explore on the interactive board
Commodore Capital LP disclosed 33 US equity positions worth $1.7bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is RLAY at 13.4% of the reported book, followed by ELVN, ALKS. The top ten holdings are 68.2% of the book, and the portfolio behaves like about 16 equal-weight positions. Versus the prior filing it opened 5 new positions, added to 6, reduced 9 and exited 8. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Commodore Capital LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 5 new, 6 added, 9 reduced, 8 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | RLAY RELAY THERAPEUTICS INC | Healthcare | 13.4% | $224.5m | 12,000,000 | -29% | reduced |
| 2 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 9.9% | $166.2m | 3,275,000 | 0% | held |
| 3 | ALKS ALKERMES PLC | Healthcare | 9.4% | $157.2m | 3,000,000 | -29% | reduced |
| 4 | COGT COGENT BIOSCIENCES INC | Healthcare | 7.0% | $118.0m | 3,050,000 | 6% | added |
| 5 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 6.0% | $101.5m | 5,650,000 | 0% | held |
| 6 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 5.6% | $94.1m | 2,000,000 | 0% | held |
| 7 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 4.5% | $75.2m | 846,786 | -56% | reduced |
| 8 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 4.3% | $71.9m | 2,723,196 | 0% | held |
| 9 | TNGX TANGO THERAPEUTICS INC | Healthcare | 4.2% | $70.3m | 2,250,000 | – | new |
| 10 | EYPT EYEPOINT INC | Healthcare | 3.9% | $65.8m | 4,600,000 | 63% | added |
| 11 | TYRA TYRA BIOSCIENCES INC | Healthcare | 3.6% | $59.9m | 1,875,000 | -24% | reduced |
| 12 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 3.0% | $50.4m | 1,939,000 | 0% | held |
| 13 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 3.0% | $50.2m | 1,350,000 | -50% | reduced |
| 14 | PHVS PHARVARIS N V | Healthcare | 2.9% | $49.3m | 1,425,000 | -26% | reduced |
| 15 | LB PHARMACEUTICALS INC | 2.9% | $48.7m | 1,500,000 | 0% | held | |
| 16 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 2.3% | $38.9m | 1,415,000 | 42% | added |
| 17 | EDIT EDITAS MEDICINE INC | Healthcare | 1.7% | $28.8m | 8,889,000 | – | new |
| 18 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 1.7% | $28.7m | 250,000 | -67% | reduced |
| 19 | CATX PERSPECTIVE THERAPEUTICS INC | 1.3% | $21.6m | 6,336,782 | 0% | held | |
| 20 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.3% | $21.3m | 8,695,652 | 0% | held |
| 21 | ZURA ZURA BIO LTD | Healthcare | 1.1% | $19.2m | 3,250,000 | 0% | held |
| 22 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.1% | $18.8m | 1,018,319 | 111% | added |
| 23 | INFLARX NV | 1.0% | $16.4m | 7,300,000 | – | new | |
| 24 | ANTX AN2 THERAPEUTICS INC | 0.8% | $14.2m | 2,933,680 | 26% | added | |
| 25 | NUVALENT INC | 0.7% | $12.3m | 100,000 | -88% | reduced | |
| 26 | SABS SAB BIOTHERAPEUTICS INC | 0.7% | $11.2m | 2,870,000 | -35% | reduced | |
| 27 | IKT INHIBIKASE THERAPEUTICS INC | 0.7% | $11.0m | 5,397,488 | 0% | held | |
| 28 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.6% | $9.9m | 1,425,000 | 125% | added |
| 29 | PEPG PEPGEN INC | Healthcare | 0.5% | $8.1m | 4,475,000 | 0% | held |
| 30 | RESEARCH ALLIANCE CORP III | 0.3% | $5.3m | 500,000 | – | new | |
| 31 | HELIX ACQUISITION CORP III | 0.3% | $5.3m | 500,000 | 0% | held | |
| 32 | LONA LEONABIO INC | 0.3% | $4.3m | 464,398 | 0% | held | |
| 33 | VTGN VISTAGEN THERAPEUTICS INC | 0.0% | $630.2k | 2,788,620 | – | new |
What did Commodore Capital LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| ERAS ERASCA INC | 21.9% | $51.4m |
| XENE XENON PHARMACEUTICALS INC | 20.4% | $48.0m |
| NRIX NURIX THERAPEUTICS INC | 15.0% | $35.3m |
| CRVS CORVUS PHARMACEUTICALS INC | 14.1% | $33.0m |
| SLNOEUR SOLENO THERAPEUTICS INC | 9.3% | $21.8m |
| OCUL OCULAR THERAPEUTIX INC | 9.3% | $21.8m |
| PALI PALISADE BIO INC | 5.4% | $12.6m |
| KPTI KARYOPHARM THERAPEUTICS INC | 4.6% | $10.9m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 91.0% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Commodore Capital LP's portfolio?
Across every quarter Commodore Capital LP has filed, its median largest position is 11.6% of the book and its median top-ten weight is 64.8%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 8.0 completed holding spells, the median lasted 1.0 quarters; 33.0 positions are still open and their final length is unknown.